Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
Titel:
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
Auteur:
Jebbink, M. de Langen, A.J. Monkhorst, K. Boelens, M.C. van den Broek, D. van der Noort, V. de Gooijer, C.J. Mahn, M. van der Wekken, A.J. Hendriks, L. Hashemi, S.M.S. Paats, M.S. Dingemans, A.C. Smit, E.F.